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INTRODUCTION {#sec1-1}
============

Human bocavirus (HBoV) was discovered in 2005 in nasopharyngeal aspirates of Swedish children with lower respiratory tract infection \[Allander et al., [2005](#bib4){ref-type="ref"}\]. Respiratory infection with HBoV occurs worldwide with frequencies ranging from 1.5% to 19.3% in respiratory samples of children \[Bastien et al., [2006](#bib7){ref-type="ref"}; Weissbrich et al., [2006](#bib49){ref-type="ref"}; Neske et al., [2007](#bib40){ref-type="ref"}; Bonzel et al., [2008](#bib9){ref-type="ref"}; Brieu et al., [2008](#bib10){ref-type="ref"}; von Linstow et al., [2008](#bib48){ref-type="ref"}; Albuquerque et al., [2009](#bib2){ref-type="ref"}; Fabbiani et al., [2009](#bib18){ref-type="ref"}; Calvo et al., [2010](#bib11){ref-type="ref"}; Kaida et al., [2010](#bib24){ref-type="ref"}; Moriyama et al., [2010](#bib39){ref-type="ref"}; Midulla et al., [2010](#bib37){ref-type="ref"}; Miron et al., [2010](#bib38){ref-type="ref"}; Song et al., [2010](#bib44){ref-type="ref"}\]. HBoV was also detected in stool specimens of children admitted to hospital for acute gastroenteritis \[Albuquerque et al., [2007](#bib1){ref-type="ref"}; Lee et al., [2007](#bib30){ref-type="ref"}; Chieochansin et al., [2008](#bib12){ref-type="ref"}; Kapoor et al., [2009](#bib25){ref-type="ref"}, [2010](#bib26){ref-type="ref"}; Szomor et al., [2009](#bib45){ref-type="ref"}; Chow et al., [2010](#bib13){ref-type="ref"}\]. Infections are known in children and adults, but children younger than 2 years appear to be most at risk of HBoV infection. HBoV was found recently in children with lower respiratory tract infection, and several studies show an association between HBoV and acute respiratory symptoms, which is consistent with a causal role \[Allander et al., [2005](#bib4){ref-type="ref"}; Kesebir et al., [2006](#bib27){ref-type="ref"}; Manning et al., [2006](#bib34){ref-type="ref"}; Fry et al., [2007](#bib20){ref-type="ref"}; Maggi et al., [2007](#bib33){ref-type="ref"}\]. Most studies confirmed a high rate of coinfections, where HBoV occurs simultaneously with other respiratory viruses, thereby making the association of HBoV with disease more complex \[Allander, [2008](#bib3){ref-type="ref"}; Schildgen et al., [2008](#bib42){ref-type="ref"}\]. There are also a few reports of the persistence of HBoV DNA in respiratory and blood samples, or prolonged shedding of HBoV in infected patients \[Allander et al., [2007](#bib5){ref-type="ref"}; von Linstow et al., [2008](#bib48){ref-type="ref"}; Martin et al., [2010](#bib36){ref-type="ref"}\].

The aim of this study was to assess the frequency and clinical features of HBoV infections in Slovenian children admitted to hospital with respiratory tract infections. Viral loads of HBoV DNA were determined in respiratory samples, and sequencing of amplified HBoV DNA was used to characterize virus strains present in the population. Clinical features of HBoV infections were compared with infections with other frequently detected respiratory viruses, such as respiratory syncytial virus (RSV), human rhinoviruses (hRV), human metapneumoviruses (hMPV), and human coronaviruses (hCoV).

PATIENTS AND METHODS {#sec1-2}
====================

Study Population and Clinical Specimens {#sec2-1}
---------------------------------------

Between April 2007 and March 2009, 891 respiratory samples from 760 pediatric patients admitted to hospital with respiratory tract infection were submitted for routine testing of respiratory viruses from University Children\'s Hospital in Ljubljana and University Medical Centre in Ljubljana. Virtually all of the patients from Pulmonology department of Pediatric Children\'s hospital that were admitted to hospital between April 2007 and March 2009 were included in the study. A majority of children with lower respiratory tract infection which require hospital treatment and are located in central part of Slovenia are treated in this department every year. Each of the 891 samples represented a different hospitalization event. During the study, 664 patients were hospitalized once, 76 patients twice, and 20 patients three times or more.

Of 891 respiratory samples, 94% were nasopharyngeal swabs, 4% were throat swabs, and 2% were tracheal aspirates and bronchoalveolar lavages. Flocked swabs were transported in 2 ml of liquid viral transport medium (Copan Italia S.p.A., Brescia, Italy). Clinical and laboratory data were collected retrospectively from medical records and anonymized.

The medical records were reviewed for all studied patients and episodes, regardless of diagnostic results, including patients negative for all viruses tested. Since the study was retrospective, informed consent from the patients was not obtained, but the research was approved by the National Medical Ethics Committee of the Republic of Slovenia. Also, the principles of the Helsinki Declaration, the Oviedo Convention on Human Rights and Biomedicine and the Slovene Code of Medical Deontology were followed in the conduct of this research. No additional sample was taken from the patients for the purpose of the study.

Nucleic Acid Extraction and HBoV Quantitative Real‐Time PCR {#sec2-2}
-----------------------------------------------------------

Automatic nucleic acid extraction was carried out using a total nucleic acid isolation kit on a MagNa Pure Compact instrument (Roche Applied Science, Mannheim, Germany), according to the manufacturer\'s instructions. One hundred ninety‐five microliters of respiratory sample was used for extraction, and 5 µl of equine herpesvirus 1 (EHV1) was added as an internal control, to give a final volume of 200 µl. Nucleic acids were eluted in 100 µl of elution buffer. EHV1 was added and titrated to yield a threshold cycle (C~t~) value of approximately 30 in real‐time PCR.

Multiplex real‐time PCR for HBoV and EHV1 was performed using Platinum Quantitative PCR SuperMix‐UDG kit (Invitrogen, Carlsbad, CA). Amplification of part of the NS1 gene of HBoV and part of the EHV1 glycoprotein B gene was performed using previously described assays \[Diallo et al., [2006](#bib17){ref-type="ref"}; Lu et al., [2006](#bib31){ref-type="ref"}\]. Each 25 µl of PCR mixture contained 2.5 µl of nucleic acid extract. Amplification was conducted using a StepOne instrument (Applied Biosystems, Foster City, CA). For standard curve generation, parts of the NS1 and NP1 genes of HBoV DNA were cloned previously and used as standards in serial dilutions \[Lu et al., [2006](#bib31){ref-type="ref"}\].

Testing for Other Respiratory Viruses {#sec2-3}
-------------------------------------

The samples were tested routinely for the presence of the antigens of respiratory viruses, by direct immunofluorescence assay (DFA). The antigens of adenovirus (AdV), RSV, influenza viruses A and B (Flu A/B), and parainfluenza viruses 1--3 (PIV 1--3) were detected using monoclonal antibodies (Oxoid, Cambridge, UK). Aliquots of samples were used for detection of viruses by DFA, and all samples were stored frozen prior to nucleic acid extraction and further analysis.

All samples were tested by RT‐PCR for hRV, hMPV, and hCoV, as described previously \[Maertzdorf et al., [2004](#bib32){ref-type="ref"}; Scheltinga et al., [2005](#bib41){ref-type="ref"}; Kuypers et al., [2007](#bib29){ref-type="ref"}\].

Sequencing of HBoV DNA {#sec2-4}
----------------------

Twenty‐five HBoV DNA‐positive samples (viral load \>10^5^ copies/ml of sample) were selected randomly for direct sequencing. The 1,136 bp VP1/VP2 gene region of the HBoV genome was amplified separately using Promega PCR Master Mix (Promega, Madison, WI). PCR products were purified and sequenced subsequently using BigDye terminator chemistry on an ABI PRISM 310 genetic analyzer (Applied Biosystems).

Statistical Analysis {#sec2-5}
--------------------

Statistical analysis was carried out using the SPSS (15.0) software package (SPSS, Inc., Chicago, IL). Categorical variables between groups were compared using the chi square test or the two‐tailed Fisher\'s exact test. For continuous variables, comparisons were made using the nonparametric Mann--Whitney *U*‐test. *P* \< 0.05 was considered to be significant.

RESULTS {#sec1-3}
=======

Patient Characteristics {#sec2-6}
-----------------------

During the study period, there were 891 different admissions to hospital of 760 children aged 0--17 years. The majority of children were below the age of 3 years, with 36.2% of children aged between 0 and 12 months, 32.7% of children aged between 13 and 24 months, and 19.9% of children aged between 25 and 36 months. Only 11.2% of the study population was older than 3 years of age. The median age of the study population was 17 months, and 56.1% were males. Lower respiratory tract infection was diagnosed in 96% of the study population, and bronchiolitis was diagnosed in 59.6% of cases, followed by radiologically confirmed pneumonia in 19% of cases. An underlying condition (cardiac and pulmonary conditions, prematurity, and congenital immunodeficiency) was observed in 27.3% of cases. Recurrent wheezing and asthma were identified in 9% and 6.7% of cases, respectively. In this study, 2.7% of children admitted to hospital were transferred to the intensive care unit.

Virus Identification {#sec2-7}
--------------------

At least one potential viral pathogen was detected in 75% (668/891) of respiratory samples. Single respiratory viral infections were detected in 75.3% (503/668) of the positive samples and coinfections in 24.7% (165/668). Infection with hRV was detected in 33.1% of all patients admitted to hospital, RSV in 23.5%, and HBoV in 18.4%. Infections with hMPV and hCoV were less frequent and were detected only in 9% and 8.4% of patients, respectively. Adenoviruses, influenza virus A and B, and parainfluenza viruses 1 and 3 were detected in 0.8%, 0.3%, 0.6%, and 0.9% of cases, respectively. Seasonal variation was observed in the respiratory viruses detected most frequently, with a high HBoV infection rate in late winter and early spring, and very low or no HBoV infection rate in summer. A significant difference in the annual frequency of HBoV infections was observed between the two winter seasons of 2007--2008 (111/503, 22.1%) and 2008--2009 (53/388, 13.7%) (*P* = 0.001). Seasonal variations in HBoV, and the other respiratory viruses detected most frequently, are shown in Figure [1](#fig1){ref-type="fig"}.

![Seasonal distribution of HBoV, hRV, RSV, hMPV, and hCoV, five respiratory viruses detected most frequently among children admitted to hospital are shown.](JMV-84-99-g001){#fig1}

HBoV was detected as a single pathogen in 40.2% (66/164) of HBoV DNA‐positive respiratory samples. hRV, RSV, hMPV, and hCoV were found as single pathogens in 71.5% (211/295), 68.4% (143/209), 61.2% (49/80), and 28% (21/75) of individual virus‐positive samples, respectively (Fig. [2](#fig2){ref-type="fig"}).

![Comparison of HBoV median viral load between children where HBoV was found as a sole pathogen and children with HBoV coinfection.](JMV-84-99-g002){#fig2}

The viruses found most frequently in HBoV coinfections were hRV in 53.1% of respiratory samples (52), RSV in 28.6% (28), human metapneumovirus in 17.3% (17), hCoV in 10.2% (10), influenza virus A in 1% (1), and parainfluenza virus 3 in 1% (1).

Clinical Characteristics of Children With an HBoV Single Infection {#sec2-8}
------------------------------------------------------------------

HBoV DNA was detected in 18.4% (164/891) of respiratory samples, which represented 20.8% (158/760) of the patients studied. HBoV was detected as a single pathogen in 7.4% (66/891) of respiratory samples.

The median age of children with single HBoV infection was 17 months, and males were infected more frequently (*P* = 0.027). The median duration of hospitalization and oxygen therapy was 4.5 and 2 days, respectively. The majority of HBoV‐positive children (53%) were aged in the range of 13--24 months (*P* = 0.003). Bronchiolitis was the leading diagnosis (63.6%), followed by pneumonia (24.2%) and recurrent wheezing (9.1%). Only two (3%) children with HBoV single infection had upper respiratory tract infection.

The symptoms reported most frequently were dyspnea, cough, hypoxia, rhinorrhea, and wheezing. Fever, gastrointestinal symptoms, and conjunctivitis were present, but less frequently. Fourteen patients (21.2%) had a single HBoV infection with underlying diseases. Five patients had cardiac/pulmonary or other congenital underlying diseases. There were six cases of prematurity (\<37 weeks), two cases of prematurity and cardiac/pulmonary or other congenital underlying diseases, and one patient with congenital immunodeficiency (Table [I](#tbl1){ref-type="table"}).

###### 

Clinical, Laboratory, and Demographic Characteristics of Studied Population and HBoV DNA‐Positive Children, Classified According to HBoV Single or HBoV Coinfection

  Characteristics                                                                   HBoV single infection   HBoV mixed infection   All HBoV infected   Study population
  --------------------------------------------------------------------------------- ----------------------- ---------------------- ------------------- ------------------
  Demographic data                                                                                                                                     
   Number of subjects                                                               n = 66                  n = 98                 n = 164             n = 891
   Age, median (months)                                                             17                      16                     16                  17
   Gender---F:M ratio                                                               1:1.75                  1:1.51                 1:1.56              1:1.28
   Hospitalization in days, median (range)                                          4.5 (1--13)             4 (1--15)              4 (1--15)           4 (1--25)
   Oxygen therapy in days, median (range)                                           2 (0--12)               2 (0--14)              2 (0--14)           2 (0--22)
  Underlying disease                                                                                                                                   
   Prematurity (\<37 weeks)                                                         8 (12.1%)               8 (8.2%)               16 (9.8%)           97 (10.9%)
   Immunodeficiency                                                                 1 (1.5%)                0                      1 (0.6%)            11 (1.2%)
   Other important underlying diseases (cardiac, pulmonary, congenital disorders)   7 (10.6%)               14 (14.3%)             21 (12.8%)          172 (19.3%)
  Clinical findings                                                                                                                                    
   Fever \>38°C                                                                     23 (34.8%)              26 (26.5%)             49 (29.9%)          241 (27%)
   Cough                                                                            59 (89.4%)              86 (87.8%)             145 (88.4%)         718 (80.6%)
   Rhinorrhea                                                                       44 (66.7%)              70 (71.4%)             114 (69.5%)         538 (60.4%)
   Dyspnea                                                                          59 (89.4%)              93 (94.9%)             152 (92.7%)         792 (88.9%)
   Wheezing                                                                         37 (56.1%)              63 (64.3%)             100 (61%)           507 (56.9%)
   Conjunctivitis                                                                   3 (4.5%)                8 (8.2%)               11 (6.7%)           38 (4.3%)
   Vomiting/diarrhea                                                                7 (10.6%)               11 (11.2%)             18 (11%)            74 (8.3%)
   Otitis                                                                           4 (6.1%)                7 (7.1%)               11 (6.7%)           34 (3.8%)
  Laboratory findings                                                                                                                                  
   CRP \>8 mg/L                                                                     38/63 (60.3%)           52/98 (53%)            90/161 (55.9%)      455/856 (53.2%)
   WBC × 10^9^ cells/L, median                                                      n = 65, 13.5            n = 98, 11.65          n = 163, 12.8       n = 868, 12.4
   Hypoxia (sat. O~2~ \<94%)                                                        53 (80.3%)              80 (81.6%)             133 (81.1%)         650 (73%)
  Chest radiographic findings                                                                                                                          
   X‐ray performed                                                                  17 (25.8%)              19 (19.3%)             36 (21.9%)          257 (28.8%)
   X‐ray pathology (infiltrates, hyperinflation)                                    16 (24.2%)              18 (18.4%)             34 (20.7%)          251 (28.2%)
  Final diagnosis                                                                                                                                      
   Upper respiratory tract infection                                                2 (3%)                  2 (2%)                 4 (2.4%)            36 (4%)
   Lower respiratory tract infection                                                64 (97%)                96 (98%)               160 (97.6%)         855 (96%)
   Pneumonia                                                                        16 (24.2%)              14 (14.3%)             30 (18.3%)          169 (19%)
   Bronchiolitis                                                                    42 (63.6%)              71 (72.4%)             113 (68.9%)         531 (59,6%)
   Bronchitis                                                                       0                       1 (1.1%)               1 (0.6%)            10 (11.2%)
   Recurrent wheezing                                                               6 (9.1%)                7 (7.1%)               13 (7.9%)           82 (9%)
   Asthma                                                                           0                       3 (3.1%)               3 (1.8%)            70 (6.7%)

HBoV, human bocavirus; F:M, female:male; CRP, C reactive protein; WBC, white blood cells.
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HBoV Viral Load {#sec2-9}
---------------

HBoV viral loads in the respiratory samples of children with acute respiratory tract infection ranged from 2.0 × 10^3^ to 9.1 × 10^10^ copies/ml of sample material.

In this study, the HBoV viral loads of children with HBoV as a single pathogen were compared with the viral loads of children with coinfections. A significant difference was found between the median value of HBoV viral load for the two groups (7.4 × 10^5^ copies/ml vs. 2.6 × 10^4^ copies/ml; *P* = 0.005) (Fig. [3](#fig3){ref-type="fig"}, Table [II](#tbl2){ref-type="table"}).

![Frequencies of respiratory viral single infections among viruses detected most frequently in children are shown, 72% of all hCoV infections and only 28.5% of all hRV infections have been found as coinfection.](JMV-84-99-g003){#fig3}

###### 

Comparison of the Median Value of the HBoV DNA Viral Load in Children With a Single HBoV Infection and Children With HBoV Coinfection

  Characteristics                                                                                 Median viral load in children with HBoV infection (copies/ml)   *P*‐value              
  ----------------------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------- -----------
  Demographic data                                                                                                                                                                       
   Gender                                                                                                                                                                                
    Female                                                                                        1.8 × 10^7^ (n = 24)                                            1.0 × 10^4^ (n = 39)   **0.005**
    Male                                                                                          5.4 × 10^5^ (n = 42)                                            4.3 × 10^4^ (n = 59)   0.293
   Age groups                                                                                                                                                                            
    0--12 months                                                                                  2.6 × 10^4^ (n = 16)                                            2.3 × 10^4^ (n = 24)   
    24 months                                                                                     4.1 × 10^7^ (n = 35)                                            1.8 × 10^6^ (n = 54)   **0.005**
    ≥25 months                                                                                    1.9 × 10^4^ (n = 15)                                            1.1 × 10^4^ (n = 20)   
  Underlying disease                                                                                                                                                                     
   Prematurity, congenital immunodeficiency, or other congenital (pulmonary, cardiac) disorders   4.1 × 10^7^ (n = 14)                                            1.2 × 10^4^ (n = 19)   **0.001**
  Laboratory findings                                                                                                                                                                    
   CRP \<8 mg/L                                                                                   5.2 × 10^6^ (n = 25)                                            1.4 × 10^4^ (n = 46)   **0.001**
   WBC \>10 × 10^9^ cells/ml                                                                      7.4 × 10^5^ (n = 54)                                            4.3 × 10^4^ (n = 65)   **0.033**
   Hypoxia (sat. O~2~ \<94%)                                                                      5.3 × 10^5^ (n = 53)                                            3.2 × 10^4^ (n = 80)   **0.044**
  Final diagnosis                                                                                                                                                                        
   Upper respiratory tract infection                                                              1.8 × 10^4^ (n = 2)                                             6.0 × 10^7^ (n = 2)    0.121
   Lower respiratory tract infection                                                              8.9 × 10^5^ (n = 64)                                            2.5 × 10^4^ (n = 96)   **0.003**
   Pneumonia                                                                                      2.2 × 10^7^ (n = 16)                                            1.3 × 10^4^ (n = 14)   0.096
   Bronchiolitis                                                                                  7.2 × 10^5^ (n = 42)                                            3.4 × 10^4^ (n = 71)   **0.044**
   Bronchitis                                                                                     0                                                               2.3 × 10^5^ (n = 1)    ND
   Recurrent wheezing                                                                             8.6 × 10^4^ (n = 6)                                             1.9 × 10^4^ (n = 7)    0.391
   Asthma                                                                                         0                                                               3.5 × 10^3^ (n = 3)    ND

HBoV, human bocavirus; CRP, C‐reactive protein; WBC, white blood cells; ND, not done.

*P*‐values \<0.05 are significant. Statistical values are in bold.
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In 66 children with single HBoV infection, a relationship was observed with prematurity, child age, and HBoV DNA load. Prematurely born children had a higher median HBoV DNA load compared with children born at term (*P* = 0.015). Children aged between 13 and 24 months had a higher median HBoV DNA load compared with children in the other two age groups (age group 0--12 months: *P* = 0.031; age group \>25 months: *P* = 0.007). The median HBoV DNA viral load was higher in females (1.8 × 10^7^ copies/ml), children with pneumonia (2.2 × 10^7^ copies/ml), and children with underlying diseases (4.1 × 10^7^ copies/ml), but the differences were not significant (*P* = 0.54; *P* = 0.6; *P* = 0.1), data not shown.

In children with HBoV single infection, stratification of clinical data on the basis of HBoV DNA load did demonstrate significant differences between children with high (\>10^5^ HBoV DNA copies/ml, n = 39) and low (\<10^5^ HBoV DNA copies/ml, n = 27) HBoV DNA load in their respiratory samples. In the group of children with high HBoV DNA load wheezing was detected more frequently compared to children with low HBoV DNA load (*P* = 0.037) and the majority of children were within age group between 12 and 24 months (*P* = 0.002).

HBoV Single Infection Versus hRV, RSV, hMPV, and hCoV Single Infections {#sec2-10}
-----------------------------------------------------------------------

Duration of hospitalization and oxygen therapy in patients with HBoV infection were longer compared with children with hRV infection (*P* = 0.001, *P* = 0.009). Children with HBoV infection had less frequently underlying diseases (*P* = 0.05). Among children infected with HBoV, fever (\>38°C), cough, hypoxia, and conjunctivitis were present more frequently compared with children infected with hRV (*P* = 0.006, *P* = 0.034, *P* = 0.01, *P* = 0.043). Asthma was diagnosed more frequently in children with hRV infection compared with HBoV, where no subjects were diagnosed with asthma (*P* = 0.001).

Compared with RSV infection, HBoV‐infected children were older (*P* \< 0.001), and there was a tendency to more male infections (*P* = 0.052). There was no significant difference in the duration of hospitalization and/or oxygen therapy. The median value of the WBC count was significantly lower in RSV‐positive patients compared with HBoV‐positive patients (*P* = 0.001).

Compared with hMPV‐infected children, the children with HBoV infection had a cough and rhinorrhea more frequently (*P* = 0.045, *P* = 0.038), and the median value of leukocytes was significantly higher (*P* \< 0.001).

The duration of oxygen therapy was shorter in hCoV‐infected patients compared with children with HBoV infection (*P* = 0.012). Children with HBoV infection required more frequently oxygen therapy (*P* = 0.021), but had less frequently underlying diseases (*P* = 0.005), when compared with hCoV‐infected children. Cough and rhinorrhea were more frequent in children with HBoV infection (*P* = 0.007, *P* = 0.005), and asthma was diagnosed more frequently in hCoV‐infected children (*P* = 0.013). The clinical, laboratory, and demographic characteristics of children with HBoV single infections were compared with those with RSV, hRV, hMPV, and hCoV single infections (Table [III](#tbl3){ref-type="table"}).

###### 

Comparison of Clinical Features of Children With Different Single‐Virus Respiratory Infections

  Characteristics                                                                                                HBoV            hRV[a](#fn2){ref-type="fn"}   RSV[b](#fn3){ref-type="fn"}   hMPV[c](#fn4){ref-type="fn"}   hCoV[d](#fn5){ref-type="fn"}   *P*‐value
  -------------------------------------------------------------------------------------------------------------- --------------- ----------------------------- ----------------------------- ------------------------------ ------------------------------ ----------------------------------------------------------------------------------------------------------------------------
  Demographic data                                                                                                                                                                                                                                         
   Number of subjects                                                                                            n = 66          n = 211                       n = 143                       n = 49                         n = 21                         
   Age (median)                                                                                                  17              20                            7                             21                             12                             0.07[a](#fn2){ref-type="fn"}, **\<0.001** ^**b**^, 0.289[c](#fn4){ref-type="fn"}, 0.161[d](#fn5){ref-type="fn"}
  Age groups                                                                                                                                                                                                                                               
   0--12 months                                                                                                  16 (24.2%)      59 (28%)                      95 (66.4%)                    14 (28.6%)                     11 (52.4%)                     **0.01** ^**a**^, **\<0.001** ^**b**^, **0.039** ^**c**^, **0.015** ^**d**^
   13--24 months                                                                                                 35 (53%)        70 (33.2%)                    21 (14.7%)                    15 (30.6%)                     4 (19%)                        
   ≥25 months                                                                                                    15 (22.7%)      82 (38.9%)                    27 (18.9%)                    20 (40.8%)                     6 (28.6%)                      
   Gender---F:M ratio                                                                                            1:1.75          1:1.37                        1.1:1                         1.1:1                          1:1                            0.393[a](#fn2){ref-type="fn"}, 0.052[b](#fn3){ref-type="fn"}, 0.131[c](#fn4){ref-type="fn"}, 1[d](#fn5){ref-type="fn"}
   Hospitalization in days, median (range)                                                                       4.5 (1--13)     4 (1--25)                     5 (1--14)                     6 (1--14)                      4 (2--12)                      **0.001** ^**a**^, 0.1[b](#fn3){ref-type="fn"}, 0.201[c](#fn4){ref-type="fn"}, 0.54[d](#fn5){ref-type="fn"}
   Oxygen therapy in days, median (range)                                                                        2 (0--12)       1 (0--22)                     3 (0--10)                     3 (0--10)                      1 (0--6)                       **0.009** ^**a**^, 0.52[b](#fn3){ref-type="fn"}, 0.721[c](#fn4){ref-type="fn"}, **0.012** ^**d**^
  Underlying disease                                                                                                                                                                                                                                       
   Prematurity (\<37 weeks), congenital immunodeficiency and/or other cardiac, pulmonary, congenital disorders   14 (21.20%)     74 (35.1%)                    29 (20.3%)                    13 (26.5%)                     12 (57.1%)                     **0.05** ^**a**^, 0.856[b](#fn3){ref-type="fn"}, 0.514[c](#fn4){ref-type="fn"}, **0.005** ^**d**^
  Clinical findings                                                                                                                                                                                                                                        
   Fever \>38°C                                                                                                  23 (34.8%)      38 (18%)                      49 (34.3%)                    18 (36.7%)                     5 (23.8%)                      **0.006** ^**a**^, 1[b](#fn3){ref-type="fn"}, 0.846[c](#fn4){ref-type="fn"}, 0.428[d](#fn5){ref-type="fn"}
   Cough                                                                                                         59 (89.4%)      162 (76.8%)                   124 (86.7%)                   36 (73.5%)                     13 (61.9%)                     **0.034** ^**a**^, 0.658[b](#fn3){ref-type="fn"}, **0.045** ^**c**^, **0.007** ^**d**^
   Rhinorrhea                                                                                                    44 (66.7%)      131 (62.1%)                   104 (72.7%)                   23 (46.9%)                     6 (28.6%)                      0.56[a](#fn2){ref-type="fn"}, 0.414[b](#fn3){ref-type="fn"}, **0.038** ^**c**^, **0.005** ^**d**^
   Dyspnea                                                                                                       59 (89.4%)      196 (92.9%)                   135 (94.4%)                   44 (89.8%)                     16 (76.2%)                     0.433[a](#fn2){ref-type="fn"}, 0.248[b](#fn3){ref-type="fn"}, 1[c](#fn4){ref-type="fn"}, 0.152[d](#fn5){ref-type="fn"}
   Wheezing                                                                                                      37 (56.1%)      133 (63%)                     73 (51%)                      27 (55.1%)                     12 (57.1%)                     0.315[a](#fn2){ref-type="fn"}, 0.552[b](#fn3){ref-type="fn"}, 1[c](#fn4){ref-type="fn"}, 1[d](#fn5){ref-type="fn"}
   Conjunctivitis                                                                                                3 (4.5%)        1 (0.5%)                      10 (7%)                       4 (8.2%)                       2 (9.5%)                       **0.043** ^**a**^, 0.759[b](#fn3){ref-type="fn"}, 0.457[c](#fn4){ref-type="fn"}, 0.59[d](#fn5){ref-type="fn"}
   Vomiting/diarrhea                                                                                             7 (10.6%)       12 (5.7%)                     14 (9.8%)                     4 (8.2%)                       1 (4.8%)                       0.171[a](#fn2){ref-type="fn"}, 0.81[b](#fn3){ref-type="fn"}, 0.756[c](#fn4){ref-type="fn"}, 0.673[d](#fn5){ref-type="fn"}
   Otitis                                                                                                        4 (6.1%)        8 (3.8%)                      4 (2.8%)                      2 (4.1%)                       2 (9.5%)                       0.488[a](#fn2){ref-type="fn"}, 0.265[b](#fn3){ref-type="fn"}, 1[c](#fn4){ref-type="fn"}, 0.628[d](#fn5){ref-type="fn"}
  Laboratory findings                                                                                                                                                                                                                                      
   CRP \>8 mg/L                                                                                                  38/63 (60.3%)   119/202 (58.9%)               68/136 (50%)                  25/47 (53.2%)                  11/21 (52.4%)                  0.561[a](#fn2){ref-type="fn"}, 0.285[b](#fn3){ref-type="fn"}, 0.559[c](#fn4){ref-type="fn"}, 0.323[d](#fn5){ref-type="fn"}
   WBC × 10^9^ cells/L, median                                                                                   n = 65, 13.5    n = 206, 14.45                n = 138, 9.95                 n = 48, 9.15                   n = 20, 13.95                  0.375[a](#fn2){ref-type="fn"}, **\<0.001** ^**b**^, \<**0.001** ^**c**^, 0.604[d](#fn5){ref-type="fn"}
   Hypoxia (sat. O~2~ \<94%)                                                                                     53 (80.3%)      133 (63%)                     120 (83.9%)                   38 (77.5%)                     11 (52.4%)                     **0.01** ^**a**^, 0.557[b](#fn3){ref-type="fn"}, 0.818[c](#fn4){ref-type="fn"}, **0.021** ^**d**^
  Chest radiographic findings                                                                                                                                                                                                                              
   X‐ray performed                                                                                               17 (25.8%)      45 (21.3%)                    45 (31.5%)                    18 (36.7%)                     7 (33.3%)                      0.499[a](#fn2){ref-type="fn"}, 0.421[b](#fn3){ref-type="fn"}, 0.225[c](#fn4){ref-type="fn"}, 0.578[d](#fn5){ref-type="fn"}
   X‐ray pathology (infiltrates, hyperinflation)                                                                 16 (24.2%)      42 (20.4%)                    45 (31.5%)                    18 (36.7%)                     7 (33.3%)                      0.488[a](#fn2){ref-type="fn"}, 0.327[b](#fn3){ref-type="fn"}, 0.215[c](#fn4){ref-type="fn"}, 0.571[d](#fn5){ref-type="fn"}
  Final diagnosis                                                                                                                                                                                                                                          
   Upper respiratory tract infection                                                                             2 (3%)          6 (2.8%)                      2 (1.4%)                      4 (8.2%)                       2 (9.5%)                       1[a](#fn2){ref-type="fn"}, 0.592[b](#fn3){ref-type="fn"}, 0.399[c](#fn4){ref-type="fn"}, 0.244[d](#fn5){ref-type="fn"}
   Lower respiratory tract infection                                                                             64 (97%)        205 (97.2%)                   141 (98.6%)                   45 (91.8%)                     19 (90.5%)                     1[a](#fn2){ref-type="fn"}, 0.592[b](#fn3){ref-type="fn"}, 0.399[c](#fn4){ref-type="fn"}, 0.244[d](#fn5){ref-type="fn"}
   Pneumonia                                                                                                     16 (24.2%)      35 (16.6%)                    29 (20.3%)                    12 (24.5%)                     5 (23.8%)                      0.202[a](#fn2){ref-type="fn"}, 0.588[b](#fn3){ref-type="fn"}, 1[c](#fn4){ref-type="fn"}, 1[d](#fn5){ref-type="fn"}
   Bronchiolitis                                                                                                 42 (63.6%)      116 (55%)                     104 (72.7%)                   26 (53.10%)                    11 (52.4%)                     0.255[a](#fn2){ref-type="fn"}, 0.197[b](#fn3){ref-type="fn"}, 0.338[c](#fn4){ref-type="fn"}, 0.443[d](#fn5){ref-type="fn"}
   Bronchitis                                                                                                    0               2 (0.9%)                      0                             1 (2%)                         0                              1[a](#fn2){ref-type="fn"}, ND[b](#fn3){ref-type="fn"}, 0.426[c](#fn4){ref-type="fn"}, ND[d](#fn5){ref-type="fn"}
   Recurrent wheezing                                                                                            6 (9.10%)       27 (12.8%)                    5 (3.5%)                      4 (8.2%)                       0                              0.517[a](#fn2){ref-type="fn"}, 0.105[b](#fn3){ref-type="fn"}, 1[c](#fn4){ref-type="fn"}, 0.329[d](#fn5){ref-type="fn"}
   Asthma                                                                                                        0               25 (11.8%)                    3 (2.1%)                      2 (4.1%)                       3 (14.3%)                      **0.001** ^**a**^, 0.553[b](#fn3){ref-type="fn"}, 0.179[c](#fn4){ref-type="fn"}, **0.013** ^**d**^

HBoV, human bocavirus, hRV, human rhinoviruses; RSV, respiratory syncytial virus; hMPV, human metapneumovirus; hCoV, human corona viruses; F:M, female:male; CRP, C‐reactive protein; WBC, white blood cells.

*P*‐values \<0.05 are significant. Statistical values are in bold.

Children with HBoV infection and children with hRV infection were compared.

Children with HBoV infection and children with RSV infection were compared.

Children with HBoV infection and children with hMPV infection were compared.

Children with HBoV infection and children with hCoV infection were compared.
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The clinical features of children with an HBoV single infection versus HBoV + hRV, HBoV + RSV, and HBoV + hMPV coinfection pairs were analyzed to determine whether HBoV coinfections were more severe than HBoV single infections. This analysis revealed no significant differences in the duration of hospitalization and oxygen therapy between HBoV single and dual infections (Table [IV](#tbl4){ref-type="table"}).

###### 

Comparison of Clinical Features to Assess the Severity of Illness in Children With HBoV as a Sole Pathogen and Children With HBoV Coinfections

  Characteristics                                                                                  HBoV single infection   hRV + HBoV[a](#fn6){ref-type="fn"}   RSV + HBoV[b](#fn7){ref-type="fn"}   hMPV + HBoV[c](#fn8){ref-type="fn"}   *P*‐value
  ------------------------------------------------------------------------------------------------ ----------------------- ------------------------------------ ------------------------------------ ------------------------------------- ---------------------------------------------------------------------------------------------
  Demographic data                                                                                                                                                                                                                         
   Number of subjects                                                                              n = 66                  n = 45                               n = 23                               n = 14                                
   Age median (range)                                                                              17                      16                                   10                                   20                                    0.72[a](#fn6){ref-type="fn"}, **0.005** ^**b**^, 0.358[c](#fn8){ref-type="fn"}
   Gender---F:M ratio                                                                              1:1.75                  1:1.5                                1.1:1                                1:1.8                                 0.84[a](#fn6){ref-type="fn"}, 0.221[b](#fn7){ref-type="fn"}, 1[c](#fn8){ref-type="fn"}
   Hospitalization in days, median (range)                                                         4.5 (1--13)             4 (1--11)                            5 (2--7)                             5.5 (3--15)                           0.161[a](#fn6){ref-type="fn"}, 0.594[b](#fn7){ref-type="fn"}, 0.345[c](#fn8){ref-type="fn"}
   Oxygen therapy in days, median (range)                                                          2 (0--12)               2 (0--8)                             2 (0--8)                             2.5 (0--14)                           0.701[a](#fn6){ref-type="fn"}, 0.835[b](#fn7){ref-type="fn"}, 0.598[c](#fn8){ref-type="fn"}
  Underlying disease                                                                                                                                                                                                                       
   Prematurity (\<37 weeks), immunodeficiency and other cardiac, pulmonary, congenital disorders   14 (21.2%)              12 (26.7%)                           5 (21.7%)                            2 (14.3%)                             0.505[a](#fn6){ref-type="fn"}, 1[b](#fn7){ref-type="fn"}, 0.724[c](#fn8){ref-type="fn"}
  Clinical findings                                                                                                                                                                                                                        
   Fever \>38°C                                                                                    23 (34.8%)              7 (15.6%)                            7 (30.4%)                            5 (35.7%)                             **0.03** ^**a**^, 0.801[b](#fn7){ref-type="fn"}, 1[c](#fn8){ref-type="fn"}
   Cough                                                                                           59 (89.4%)              39 (86.7%)                           23 (100%)                            8 (57.1%)                             0.766[a](#fn6){ref-type="fn"}, 0.183[b](#fn7){ref-type="fn"}, **0.009** ^**c**^
   Rhinorrhea                                                                                      44 (66.7%)              23 (51.1%)                           19 (82.6%)                           11 (78.6%)                            0.319[a](#fn6){ref-type="fn"}, 0.188[b](#fn7){ref-type="fn"}, 0.531[c](#fn8){ref-type="fn"}
   Dyspnea                                                                                         59 (89.4%)              38 (84.4%)                           23 (100%)                            12 (85.7%)                            0.139[a](#fn6){ref-type="fn"}, 0.183[b](#fn7){ref-type="fn"}, 0.653[c](#fn8){ref-type="fn"}
   Wheezing                                                                                        37 (56.1%)              28 (62.2%)                           15 (65.2%)                           9 (64.3%)                             0.56[a](#fn6){ref-type="fn"}, 0.473[b](#fn7){ref-type="fn"}, 0.767[c](#fn8){ref-type="fn"}
   Conjunctivitis                                                                                  3 (4.5%)                2 (4.4%)                             2 (8.7%)                             2 (14.3%)                             0.685[a](#fn6){ref-type="fn"}, 0.601[b](#fn7){ref-type="fn"}, 0.209[c](#fn8){ref-type="fn"}
   Vomiting/diarrhea                                                                               7 (10.6%)               3 (6.7%)                             4 (14.3%)                            1 (7.1%)                              1[a](#fn6){ref-type="fn"}, 0.465[b](#fn7){ref-type="fn"}, 1[c](#fn8){ref-type="fn"}
   Otitis                                                                                          4 (6.1%)                2 (4.4%)                             1 (4.3%)                             3 (21.4%)                             1[a](#fn6){ref-type="fn"}, 1[b](#fn7){ref-type="fn"}, 0.098[c](#fn8){ref-type="fn"}
  Laboratory findings                                                                                                                                                                                                                      
   CRP \>8 mg/L                                                                                    38/63 (60.3%)           26 (57.8%)                           8 (39.1%)                            10 (71.4%)                            1[a](#fn6){ref-type="fn"}, 0.093[b](#fn7){ref-type="fn"}, 0.549[c](#fn8){ref-type="fn"}
   WBC × 10^9^ cells/L, median                                                                     n = 65, 13.5            n = 45, 13                           n = 23, 10                           n = 14, 9.6                           0.903[a](#fn6){ref-type="fn"}, **0.001** ^**b**^, **0.003** ^**c**^
   Hypoxia (sat. O~2~ \<94%)                                                                       53 (80.3%)              38 (84.4%)                           18 (78.3%)                           12 (85.7%)                            0.841[a](#fn6){ref-type="fn"}, 0.841[b](#fn7){ref-type="fn"}, 0.841[c](#fn8){ref-type="fn"}
  Chest radiographic findings                                                                                                                                                                                                              
   X‐ray performed                                                                                 17 (25.8%)              2 (4.4%)                             3 (13%)                              4 (28.6%)                             0.363[a](#fn6){ref-type="fn"}, 0.258[b](#fn7){ref-type="fn"}, 1[c](#fn8){ref-type="fn"}
   X‐ray pathology (infiltrates, hyperinflation)                                                   16 (24.2%)              2 (4.4%)                             2 (8.7%)                             4 (28.6%)                             0.484[a](#fn6){ref-type="fn"}, 0.142[b](#fn7){ref-type="fn"}, 0.744[c](#fn8){ref-type="fn"}
  Final diagnosis                                                                                                                                                                                                                          
   Upper respiratory tract infection                                                               2 (3%)                  1 (2.2%)                             0                                    0                                     1[a](#fn6){ref-type="fn"}, 1[b](#fn7){ref-type="fn"}, 1[c](#fn8){ref-type="fn"}
   Lower respiratory tract infection                                                               64 (97%)                44 (97.8%)                           23 (100%)                            14 (100%)                             1[a](#fn6){ref-type="fn"}, 1[b](#fn7){ref-type="fn"}, 1[c](#fn8){ref-type="fn"}
   Pneumonia                                                                                       16 (24.2%)              7 (15.6%)                            3 (13%)                              2 (14.3%)                             0.193[a](#fn6){ref-type="fn"}, 0.205[b](#fn7){ref-type="fn"}, 0.338[c](#fn8){ref-type="fn"}
   Bronchiolitis                                                                                   42 (63.4%)              29 (64.4%)                           20 (87%)                             11 (78.6%)                            0.547[a](#fn6){ref-type="fn"}, **0.029** ^**b**^, 0.095[c](#fn8){ref-type="fn"}
   Bronchitis                                                                                      0                       1 (2.2%)                             0                                    0                                     0.405[a](#fn6){ref-type="fn"}, ND[b](#fn7){ref-type="fn"}, ND[c](#fn8){ref-type="fn"}
   Recurrent wheezing                                                                              6 (9.1%)                4 (8.9%)                             0                                    1 (7.15%)                             0.624[a](#fn6){ref-type="fn"}, 0.156[b](#fn7){ref-type="fn"}, 0.646[c](#fn8){ref-type="fn"}
   Asthma                                                                                          0                       3 (6.7%)                             0                                    0                                     0.064[a](#fn6){ref-type="fn"}, ND[b](#fn7){ref-type="fn"}, ND[c](#fn8){ref-type="fn"}
   HBoV median viral load (copies/ml)                                                              7.4 × 10^5^             8.1 × 10^4^                          8.8 × 10^3^                          1.5 × 10^4^                           1[a](#fn6){ref-type="fn"}, 1[b](#fn7){ref-type="fn"}, 1[c](#fn8){ref-type="fn"}

HBoV, human bocavirus; hRV, human rhinoviruse; RSV, respiratory syncytial virus; hMPV, human metapneumovirus; F:M, female:male; CRP, C‐reactive protein; WBC, white blood cells.

*P*‐values \<0.05 are significant; hCoV + HBoV dual coinfections were excluded from analyses because of low sample sizes (n = 4). Statistical values are in bold.

Children with HBoV infection and children with HBoV and hRV double coinfection were compared.

Children with HBoV infection and children with HBoV and RSV double coinfection were compared.

Children with HBoV infection and children with HBoV and hMPV double coinfection were compared.
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Phylogenetic Analysis of HBoV DNA Sequences {#sec2-11}
-------------------------------------------

Twenty‐five samples were selected at random from 66 HBoV single infections and the 1,136‐bp‐long region of the VP1/VP2 gene was amplified and sequenced. Of 25 sequences obtained, there were eight unique sequences, which were deposited in GenBank (acc. no. GQ907238--GQ907245). All sequences were variants of the HBoV ST1 or ST2 genotypes and shared sequence identity of between 98.6% and 99.9%. Two of the eight sequences showed 100% identity with the sequences deposited in GenBank.

DISCUSSION {#sec1-4}
==========

This study aimed to evaluate respiratory viral infections in a 2‐year cohort of children hospitalized in University Children\'s hospital, with an emphasis on infections caused by the HBoV discovered recently.

Of the 891 children included in this study, a possible viral etiology was determined in 75% of patients. The viruses detected most frequently were hRV, RSV, and HBoV. A previous study of a population of children admitted to hospital found an identical frequency distribution of respiratory virus infections \[Chung et al., [2007](#bib16){ref-type="ref"}\], although the median age of patients in that study was lower (8.5 months) than the cohort of patients in the current study. Comparison between different studies is always difficult, because many factors can influence the frequency of respiratory viruses detected, for example, climate, study duration, season, patient age and background, and laboratory methods used.

In this study, viral infections showed a clear seasonal distribution, as would be expected for the continental climate found in Slovenia. The current study confirmed that HBoV infections are distributed seasonally, with the highest infection rate in winter and early spring, as shown in other studies \[Foulongne et al., [2006](#bib19){ref-type="ref"}; Weissbrich et al., [2006](#bib49){ref-type="ref"}; Margaret et al., [2008](#bib35){ref-type="ref"}; von Linstow et al., [2008](#bib48){ref-type="ref"}; Vallet et al., [2009](#bib46){ref-type="ref"}; Calvo et al., [2010](#bib11){ref-type="ref"}; Christensen et al., [2010](#bib15){ref-type="ref"}\]. The HBoV case distribution and frequency differed significantly between the two seasons studied. A previous study also reported seasonality for other respiratory viruses \[Christensen et al., [2010](#bib15){ref-type="ref"}\].

Overall, the current study detected HBoV DNA in the respiratory samples of 18.4% of children admitted to hospital with respiratory tract infection. HBoV was detected as the third most commonly virus, after hRV and RSV. The prevalence of HBoV infection is among the highest compared with similar studies \[Allander et al., [2007](#bib5){ref-type="ref"}\]. Interestingly, the highest HBoV infection rate was found in children aged between 13 and 24 months. This finding agrees with previous reports, which indicate that the median age of HBoV‐infected children is between 13 and 18 months \[Foulongne et al., [2006](#bib19){ref-type="ref"}; Volz et al., [2007](#bib47){ref-type="ref"}; Bharaj et al., [2010](#bib8){ref-type="ref"}; Calvo et al., [2010](#bib11){ref-type="ref"}; Garcia‐Garcia et al., [2010](#bib22){ref-type="ref"}; Miron et al., [2010](#bib38){ref-type="ref"}; Moriyama et al., [2010](#bib39){ref-type="ref"}\]. Male children were more frequently infected with HBoV.

HBoV was found frequently with other respiratory viruses in the current study (60%), which agrees with the findings in previous reports \[Christensen et al., [2008](#bib14){ref-type="ref"}; Garcia‐Garcia et al., [2008](#bib21){ref-type="ref"}; Jacques et al., [2008](#bib23){ref-type="ref"}; Calvo et al., [2010](#bib11){ref-type="ref"}; Miron et al., [2010](#bib38){ref-type="ref"}\]. However, the median level of viral loads appeared to be significantly higher in patients with a single HBoV infection than in patients coinfected with other respiratory viruses (*P* = 0.005). These findings corroborate the results of two other previous studies \[Allander et al., [2007](#bib5){ref-type="ref"}; Brieu et al., [2008](#bib10){ref-type="ref"}\]. Allander et al. \[[2007](#bib5){ref-type="ref"}\] suggested that high HBoV DNA loads are indicative of a causative role of HBoV in respiratory tract infections, whereas low viral loads indicate asymptomatic shedding. In the present study the age of the children (12--24 months) and wheezing were associated with high HBoV DNA load.

Children aged between 13 and 24 months, and prematurely born children, had a higher median viral load compared with children in the other two age groups and children born at term. The majority of HBoV‐positive samples were detected in children aged between 13 and 24 months. These data suggest that in this age group HBoV infections are a consequence of primary infection which may more likely result in a higher viral load and this in turn may manifest as a severe clinical presentation.

In the present study, the clinical features of children with single infections caused by HBoV, hRV, RSV, hMPV, and hCoV were also assessed. The most important observation was probably that HBoV infection can result in severe disease manifestation that is virtually indistinguishable from infections caused by RSV and hMPV, as was recently described by other researchers \[Soderlund‐Venermo et al., [2009](#bib43){ref-type="ref"}; Calvo et al., [2010](#bib11){ref-type="ref"}; Garcia‐Garcia et al., [2010](#bib22){ref-type="ref"}\]. Patients with RSV and hMPV were hospitalized longer and needed longer oxygen therapy, but the differences were not statistically significant. Bronchiolitis, pneumonia, and recurrent wheezing were the most common clinical presentations of single bocavirus infections. These data agree with other published studies where these clinical presentations were detected commonly in HBoV‐infected patients. Direct comparison with other studies is difficult, because the inclusion criteria in different studies vary widely, ranging among patients suffering from acute bronchiolitis, recurrent wheezing, or unspecified respiratory tract infections.

There are also limitations in the current study. First, the retrospective nature of the study might introduce a bias into patient selection. Second, the prevalence of viruses detected by DFA testing (i.e., Flu A/B) might indicate an underestimation of the true prevalence, because of the low sensitivity of the DFA method when compared with PCR. However, the sensitivity of DFA in RSV detection was determined in other studies (unpublished data) and did not differ to any great extent \[Kuypers et al., [2006](#bib28){ref-type="ref"}; Aslanzadeh et al., [2008](#bib6){ref-type="ref"}\]. While HBoV shedding is very frequent, the true seasonality of symptomatic primary HBoV infection is difficult to study by this approach, although we found a clear seasonal distribution of infections caused by HBoV. Finally, a control group of children of the same age would be desirable. Thus, a new prospective study was commenced at the University Medical Centre in 2009, where an age‐matched control group of patients was included.

We are grateful to the Institute for Microbiology and Parasitology and the Virology Unit at the Veterinary Faculty, University of Ljubljana for providing an isolate of *Equine herpes virus 1*.
